Kaio Therapy

Kaio Therapy is a private, preclinical-stage biotech developing a novel hyperthermia-based immunotherapy platform. Its lead technology, Immune Activating Heat Therapy (IAHT), uses injected magnetic nanoparticles and an alternating magnetic field device to generate precise heat within tumors, aiming to induce necrosis and trigger a systemic, tumor-specific immune response. The company is initially targeting cutaneous tumors but anticipates expansion to other solid tumors like breast and head and neck cancers. Kaio Therapy's strategy positions IAHT both as a standalone therapy and as a potential platform to enhance other immunotherapies.

Immune Activating Heat Therapy (IAHT): A two-component hyperthermia-immunotherapy platform using intratumorally injected Magnetite Cationic Liposome (MCL) nanoparticles excited by an external Alternating Magnetic Field (AMF) device to generate precise, localized heat. This induces immunogenic cell death and enhances antigen presentation via Heat Shock Proteins (HSPs) to activate a systemic, tumor-specific immune response.

Kaio competes in the hyperthermia space with companies like BSD Medical (now part of Pyrexar) and in the broader tumor immune-activation field with developers of oncolytic viruses (e.g., Amgen's Imlygic), STING agonists, and TLR agonists. Its differentiation lies in the precise, intracellular heating mechanism designed to generate a broad, personalized antigen response.